Taken together the results of these experiments indicated that targeting CCR4 expressed on melanoma cells ameliorates their malignant phenotype in-vitro and in-vivo suggesting that CCR4 antagonists may have a therapeutic potential in melanoma. The gene discussed is CCR4; the disease is melanoma.